NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES.
Today, June 7, 2024, is the last day of trading with the unit rights that were issued in conjunction with PEPTONIC medical AB (“Peptonic” or the “Company”) rights issue of units consisting of shares and warrants, which the board of directors resolved on April 16, 2024 and was approved at the annual general meeting on May 21, 2024 (the “Rights Issue”). Unit rights that are not sold or not exercised for subscription will expire worthless.
The Rights Issue in summary:
- Subscription period: May 28, 2024 – June 12, 2024.
- Trade in unit rights: May 28, 2024 – June 7, 2024.
- Preferential rights: For each share held on the record date of May 24, 2024, one (1) unit right was received and one (1) unit right entitles to subscription of one (1) unit.
- Unit: One (1) unit contains four (4) newly issued shares and two (2) warrants of series TO5.
- Subscription price: SEK 0.04 per unit, corresponding to SEK 0.01 per share. The warrants are received free of charge.
- Issue proceeds: In the event of full subscription in the Rights Issue, the Company will receive approximately SEK 61.4 million before issue costs and in the event of full exercise of the warrants, the Company will receive an additional maximum of approximately SEK 39.9 million before issue costs.
- Underwritten level: The rights issue is underwritten to approximately 68.7 percent through subscription and underwriting commitments.
Advisers
Mangold Fondkommission AB is financial adviser and Eversheds Sutherland Advokatbyrå AB is legal adviser to Peptonic in connection with the Rights Issue.
For more information contact:
Anna Linton, CEO Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About Peptonic medical AB
Peptonic medical AB (publ) is an innovative Swedish biomedical company engaged in the development and sales of clinically proven self-care treatments and self-diagnostic rapid tests in intimate women’s health. The portfolio is sold under the brands VagiVital and Vernivia.
The company continuously aims to broaden its product portfolio through acquisitions and the development of innovative and competitive products in-house. The company’s mousse-based drug delivery technology, Venerol, and the gel base in VagiVital create favorable conditions for expanding the portfolio. Central to the growth strategy is the geographic expansion of VagiVital and Vernivia through local partners.
The company is headquartered in Stockholm, Sweden, and has subsidiaries Common Sense Marketing Inc in the USA and Peptonic Medical Ltd in Israel. Peptonic Medical was founded in 2009, and the company’s shares have been listed on the Spotlight Stock Market since 2014.
Further information regarding the company is available at www.peptonicmedical.se/en/.
Important information
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Peptonic in any jurisdiction, neither from Peptonic nor anyone else.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, the United States or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.
Within the European Economic Area, no offer is made to the public of securities in any country other than Sweden. In other Member States of the European Union, such an offer may only be made in accordance with the exceptions in the Prospectus Regulation (EU) 2017/1129.
This press release contains certain forward-looking information that reflects the Company’s present view of future events as well as financial and operational development. Words such as “intend”, “assess”, “expect”, “may”, “plan”, “believe”, “estimate” and other expressions entailing indications or predictions of future development or trends, not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information is not a guarantee of future results or development and actual outcomes may differ materially from the statements set forth in the forward-looking information.
